Article

Glaukos selected as top tech startup

Glaukos Corp. has been selected as a Red Herring Top 100 North America Tech Startup, an award honoring the year’s most promising private technology ventures. Glaukos is the only medical device company in North America to be selected for this honor.

Laguna Hills, CA-Glaukos Corp. has been selected as a Red Herring Top 100 North America Tech Startup, an award honoring the year’s most promising private technology ventures. Glaukos is the only medical device company in North America to be selected for this honor.

Red Herring editorial team members selected the most innovative companies from a pool of hundreds from across North America. They evaluated nominees on both quantitative and qualitative criteria, such as financial performance, technology innovation, quality of management, execution of strategy, market penetration, and integration into their respective industries. They also reviewed the track record and standing of startups relative to their sector peers.

“We believe Glaukos Corp. embodies the vision, drive, and innovation that define a successful entrepreneurial venture,” said Alex Vieux, publisher and chief executive officer of Red Herring.

Thomas Burns, Glaukos president and chief executive officer, said, “Glaukos is honored to be selected for this prestigious award. Through our foundational leadership in the emerging minimally invasive glaucoma surgery market class, we are striving to deliver meaningful advances in glaucoma surgery and patient care.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
© 2025 MJH Life Sciences

All rights reserved.